Literature DB >> 26915313

Male hormonal contraception: hope and promise.

Katarzyna Piotrowska1, Christina Wang1, Ronald S Swerdloff1, Peter Y Liu2.   

Abstract

Family planning is a shared responsibility, but available male-directed contraceptive methods are either not easily reversible (vasectomy) or not sufficiently effective (condom). However, roughly 20% of couples using a contraceptive method worldwide, and up to 80% in some countries, still choose a male-directed method. Male hormonal contraception is highly effective, with perfect use failure rates of 0·6% (95% CI 0·3-1·1) if sperm concentrations of less than 1 million per mL are maintained. After cessation of male hormonal contraception, sperm output fully recovers in a predictable manner, resulting in pregnancies and livebirths. Spontaneous miscarriage and fetal malformation rates after recovery of sperm output overlap those in the general population. Short-term adverse events-acne, night sweats, increased weight, and altered mood and libido-are recognised, but are generally mild. Further optimisation of specific androgen-progestin regimens and phase 3 studies of lead combinations are still needed to successfully develop an approved male hormonal contraceptive and to identify long-term side-effects.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26915313      PMCID: PMC4993687          DOI: 10.1016/S2213-8587(16)00034-6

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   44.867


  78 in total

1.  Androgens, estrogens, and bone turnover in men.

Authors:  Sundeep Khosla; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

2.  Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels.

Authors:  M Y Roth; N Ilani; C Wang; S T Page; W J Bremner; R S Swerdloff; C Dart; R Sitruk-Ware; N Kumar; D Blithe; J K Amory
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

Review 3.  The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.

Authors:  Julia Klap; Marianne Schmid; Kevin R Loughlin
Journal:  J Urol       Date:  2014-09-28       Impact factor: 7.450

Review 4.  Changing concepts: Menopausal hormone therapy and breast cancer.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  J Natl Cancer Inst       Date:  2012-03-16       Impact factor: 13.506

5.  Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy.

Authors:  Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin
Journal:  Ann Pharmacother       Date:  2014-07-02       Impact factor: 3.154

6.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

7.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

Authors:  Yi-Qun Gu; Xing-Hai Wang; Dwo Xu; Lin Peng; Li-Fa Cheng; Ming-Kong Huang; Zhen-Jia Huang; Gui-Yuan Zhang
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

Review 8.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  A new combination of testosterone and nestorone transdermal gels for male hormonal contraception.

Authors:  Niloufar Ilani; Mara Y Roth; John K Amory; Ronald S Swerdloff; Clint Dart; Stephanie T Page; William J Bremner; Regine Sitruk-Ware; Narender Kumar; Diana L Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

10.  Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception.

Authors:  Olayiwola O Oduwole; Natalia Vydra; Nicholas E M Wood; Luna Samanta; Laura Owen; Brian Keevil; Mandy Donaldson; Kikkeri Naresh; Ilpo T Huhtaniemi
Journal:  FASEB J       Date:  2014-03-05       Impact factor: 5.191

View more
  3 in total

1.  Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.

Authors:  R Ayoub; S T Page; R S Swerdloff; P Y Liu; J K Amory; A Leung; L Hull; D Blithe; A Christy; J H Chao; W J Bremner; C Wang
Journal:  Andrology       Date:  2016-12-01       Impact factor: 4.456

2.  Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.

Authors:  Sherry Wu; Fiona Yuen; Ronald S Swerdloff; Youngju Pak; Arthi Thirumalai; Peter Y Liu; John K Amory; Feng Bai; Laura Hull; Diana L Blithe; Bradley D Anawalt; Toufan Parman; Kyuri Kim; Min S Lee; William J Bremner; Stephanie T Page; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 6.134

Review 3.  Would male hormonal contraceptives affect cardiovascular risk?

Authors:  Michael Zitzmann
Journal:  Asian J Androl       Date:  2018 Mar-Apr       Impact factor: 3.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.